New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...

Therapeutics presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the ...

Visual content depicting climate activists emphasizes emotion and disruption, contrasting with the rational, data-driven ...

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ...

Companies use customer data in their decision-making, but they must know how to wield it properly. Here is the best way to ...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

In an analysis comparing bariatric surgery vs. obesity drugs in patients with diabetes and obesity, surgery was tied to lower ...

The budgetary measures taken so far by the government of Romania are insufficient for stabilising the public debt to GDP ...